Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906795 | 0.86 | LMNA (0.48) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B | |
| SCHEMBL27818016 | 0.80 | CA1 (0.39) | L3MBTL1ALDH1A1ADRA2BKMT2A | |
| SCHEMBL13086759 | 0.79 | CYP1A2 (0.41) | LMNAL3MBTL1ALDH1A1ADRA2BKDM4E | |
| SCHEMBL27701197 | 0.79 | CA1 (0.50) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B | |
| SCHEMBL8218163 | 0.79 | ADRA2A (0.48) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B | |
| SCHEMBL20314717 | 0.78 | NISCH (0.42) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B | |
| SCHEMBL2120865 | 0.78 | LMNA (0.39) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B | |
| SCHEMBL20637343 | 0.78 | LMNA (0.39) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B | |
| SCHEMBL11554545 | 0.78 | TSHR (0.45) | LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL4188090 | 0.78 | ADRA2A (0.42) | LMNAL3MBTL1ALDH1A1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521581-B2 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1707263-B1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | TOSOH CORP (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | LMNA 4553/4885L3MBTL1 3243/4885ALDH1A1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.